Mar 5 2008 -Power3 Medical Products, Inc. (OTCBB: PWRM), a leading proteomics company specializing in the development and commercialization of diagnostic tests for the early detection of breast cancer and neurodegenerative diseases, filed a U.S. Utility Patent application for forty-seven protein biomarkers of neurodegenerative disease in human blood serum.Power3 Medical has determined the blood serum concentrations of these forty-seven biomarkers in samples from more than 750 neurodegenerative disease patients and normal control subjects. The results have shown that this group of biomarkers is useful in the differential diagnosis of Alzheimer’s disease (AD) from normal control individuals, patients with non-Alzheimer’s dementias, and patients with Parkinson’s disease or ALS (Lou Gehrig’s disease). Eighteen million people worldwide have AD; because the early signs of Alzheimer’s disease are often hard to distinguish from normal signs of aging, many patients are not diagnosed until the neuronal damage caused by this disease is extensive... Power3 Medical Products' Press Release -
